CAS 100643-96-7

Indolidan

Description:

Indolidan is a chemical compound classified as a selective phosphodiesterase inhibitor, primarily targeting phosphodiesterase type 3 (PDE3). It is known for its potential use in cardiovascular therapies, particularly in the treatment of heart failure and other related conditions. The compound exhibits properties that enhance myocardial contractility and promote vasodilation, making it beneficial in improving cardiac output. Indolidan is characterized by its ability to increase intracellular cyclic AMP levels, which plays a crucial role in various cellular signaling pathways. The substance is typically administered in a clinical setting and has been studied for its pharmacokinetics, including absorption, distribution, metabolism, and excretion. While it has shown promise in clinical applications, its use may be limited by potential side effects and interactions with other medications. As with any pharmaceutical agent, careful consideration of its therapeutic benefits versus risks is essential in clinical practice.

Formula: C₁₄H₁₅N₃O₂

InChI: InChI=1S/C14H15N3O2/c1-14(2)9-7-8(3-4-11(9)15-13(14)19)10-5-6-12(18)17-16-10/h3-4,7H,5-6H2,1-2H3,(H,15,19)(H,17,18)

InChI key: InChIKey=LZCQFJKUAIWHRW-UHFFFAOYSA-N

SMILES: CC1(C)C=2C(NC1=O)=CC=C(C2)C=3CCC(=O)NN3

Synonyms:

• 2H-Indol-2-one, 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-
• LY 195115
• Indolidan
• 1,3-Dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H-indol-2-one

Indolidan

CAS: 100643-96-7

Indolidan

Purity: ≥98%

Molecular weight: 257.29g/mol

Ref: 54-BUP12419

Indolidan

CAS: 100643-96-7

Indolidan (LY 195115) induces cardiovascular and adrenal hyperplastic lesions in Fischer 344 rats. Indolidan increases the risk of cardiovascular disease.

Formula: C₁₄H₁₅N₃O₂

Purity: 98.83% - 99.82%

Color and Shape: Solid

Molecular weight: 257.29

Ref: TM-T32160